Inside the research
Merck & Co., Inc.
MRK Research profile · latest available data
Price overview
$148.78
▲ +0.80 (+0.5%)
| 52w hi | $155.53 |
|---|---|
| 52w lo | $75.39 |
| Vol | 8.29M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.26
| Short | +0.27 |
|---|---|
| Medium | +0.36 |
| Long | +0.05 |
computed 2026-09-27
Key fundamentals
Merck & Co., Inc.
Healthcare · Drug Manufacturers - General
| Market cap | $367.07B |
|---|---|
| Enterprise value | $413.89B |
| Trailing P/E | 119.02x |
| Forward P/E | 15.61x |
| EV / EBITDA | 14.34x |
| P / S (ttm) | 5.51x |
| Profit margin | 4.8% |
| Return on equity | 7.0% |
| Revenue growth | +5.1% |
| Debt / equity | 128.41 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.12 | |
| Sector | +0.08 | |
| Technical | +0.20 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Risk Metrics
| Beta vs SPX | 0.31 |
|---|---|
| Corr SPX | 0.17 |
| Annual vol | 29.0% |
| Annual ret | +16.1% |
| Sharpe | 0.56 |
| Max DD | -36.5% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $129.74 |
|---|---|
| High / Low | $150.00 / $100.00 |
| Median | $135.00 |
| Analysts | 27 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 15 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-01 | Wells Fargo | → Overweight |
| 2026-04-13 | UBS | → Buy |
| 2026-04-06 | JP Morgan | → Overweight |
| 2026-03-30 | RBC Capital | → Outperform |
| 2026-03-20 | Citigroup | → Neutral |
| 2026-03-12 | Wells Fargo | → Overweight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-04 | Earnings Release, Exhibits | read |
| 2026-05-28 | Shareholder Vote | read |
| 2026-05-22 | Other Material Event, Exhibits | read |
| 2026-04-30 | Earnings Release, Exhibits | read |
| 2026-02-03 | Earnings Release, Exhibits | read |
| 2025-12-04 | Other Material Event, Exhibits | read |
| 2025-10-30 | Earnings Release, Exhibits | read |
| 2025-09-09 | Other Material Event, Exhibits | read |
| 2025-07-29 | Earnings Release, Restructuring… | read |
| 2025-05-29 | Shareholder Vote | read |
| 2025-04-24 | Earnings Release, Exhibits | read |
| 2025-02-04 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Guindo Chirfi | EVP, Access, Policy & Com | Sell | 10.00K | $1.35M |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Sell | 80.31K | $10.72M |
| 2026-08-12 | DeLuca Richard R. | EVP&Pres, Merck Animal He | Sell | 11.10K | $1.46M |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Option exercise | 13.43K | $1.14M |
| 2026-08-12 | DeLuca Richard R. | EVP&Pres, Merck Animal He | Sell | 600 | $79.22K |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Option exercise | 41.49K | $4.89M |
| 2026-08-11 | DeLuca Richard R. | EVP&Pres, Merck Animal He | Sell | 5.43K | $718.26K |
| 2026-08-11 | DeLuca Richard R. | EVP&Pres, Merck Animal He | Sell | 7.41K | $973.16K |
| 2026-08-10 | DeLuca Richard R. | EVP&Pres, Merck Animal He | Sell | 20.78K | $2.71M |
| 2026-08-06 | DeLuca Richard R. | EVP&Pres, Merck Animal He | Sell | 805 | $105.47K |
Flow & Concentration
| Insider 180d net | -$29.98M |
|---|---|
| Insider buys / sells | 0 / 17 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 98.9% |
| HHI | 4,245 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $15.57B | 120.41M |
| Fidelity / FMR LLC | $5.84B | 45.44M |
| Capital Research / Capital World | $1.90B | 14.79M |
| Citadel Advisors | $1.18B | 9.18M |
| AQR Capital Management | $1.04B | 8.13M |
| Millennium Management | $271.70M | 2.11M |
| Bridgewater Associates | $3.89M | 30.25K |
| T. Rowe Price Group | $2.38M | 18.52M |
As of 2026-06-30
Dividends
| Yield (TTM) | 1.14% |
|---|---|
| $ / share (TTM) | $1.70 |
| 5y CAGR | +6.7% |
Annual dividend per share
| 2021 | $2.61 |
|---|---|
| 2022 | $2.80 |
| 2023 | $2.96 |
| 2024 | $3.12 |
| 2025 | $3.28 |
| 2026 | $0.85 |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $60.12B | +5.9% | |
| Net income | $18.25B | +2.2% | |
| Cash from ops | $16.47B | +12.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $148.06 | $149.98 | $147.48 | $148.78 | 8.29M |
| Sep 24 | $148.17 | $151.46 | $147.90 | $147.98 | 10.31M |
| Sep 23 | $151.32 | $152.01 | $146.89 | $148.08 | 9.70M |
| Sep 22 | $148.69 | $153.57 | $148.04 | $150.91 | 11.17M |
| Sep 21 | $146.79 | $150.49 | $145.60 | $149.50 | 7.99M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →